<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984811</url>
  </required_header>
  <id_info>
    <org_study_id>NIT-119</org_study_id>
    <nct_id>NCT04984811</nct_id>
  </id_info>
  <brief_title>NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC</brief_title>
  <official_title>A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoImmuneTech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NeoImmuneTech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy&#xD;
      and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥&#xD;
      1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not&#xD;
      received prior systemic therapy in the metastatic or locally advanced setting. Eligible&#xD;
      subjects must have measurable disease according to RECIST 1.1. This Phase II study will&#xD;
      enroll up to 83 subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The percentage of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR), per RECIST 1.1 as determined by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs first, per RECIST 1.1 as determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The proportion of subjects with a best overall response of CR, PR or SD, per RECIST 1.1 as determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The time from the first study treatment (Cycle 1, Day 1) to the first occurrence of progression or death from any cause, whichever occurs first, per RECIST .1.1 as determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The time from first study treatment (Cycle 1, Day 1) to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Non-Small Cell Lung Carcinoma</condition>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NT-I7 and atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with no prior systemic therapy for advanced NSCLC will receive 1200 μg/kg NT-I7 IM on Day 1 and every 6 weeks and atezolizumab IV 1200 mg every 3 weeks until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efineptakin alfa</intervention_name>
    <description>1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).</description>
    <arm_group_label>NT-I7 and atezolizumab</arm_group_label>
    <other_name>NT-I7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).</description>
    <arm_group_label>NT-I7 and atezolizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically or cytologically confirmed metastatic or locally advanced NSCLC,&#xD;
             and have not received prior systemic therapy. Subjects with locally advanced disease&#xD;
             must have Stage III NSCLC and are not candidates for surgical resection or definitive&#xD;
             chemoradiation&#xD;
&#xD;
          -  Tumor PD-L1 expression (TPS≥1%) as determined by PD-L1 22C3 immunohistochemistry local&#xD;
             or central assay.&#xD;
&#xD;
          -  Have measurable disease&#xD;
&#xD;
          -  Agree to provide screening biopsy (or archival tissue) at screening to assess PD-L1&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Adequate hematologic and end organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic anti-cancer therapy&#xD;
&#xD;
          -  NSCLC with EGFR, or ALK, or BRAF or ROS or RED or other genomic tumor aberrations&#xD;
             which have available therapy&#xD;
&#xD;
          -  Prior radiotherapy within 2 weeks of start of study treatment&#xD;
&#xD;
          -  Known active CNS metastasis or carcinomatous meningitis&#xD;
&#xD;
          -  Severe reactions to mAbs or IV immunoglobulin preparations&#xD;
&#xD;
          -  Autoimmune disease history in past two years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean Fan, MD</last_name>
    <phone>301-337-2283</phone>
    <email>NIT119@neoimmunetech.com; jfan@neoimmunetech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute (ICRI)</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino, CCRP</last_name>
      <phone>562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <contact_backup>
      <last_name>Sami Ali, MD</last_name>
      <phone>(562) 652-6532</phone>
      <email>sami.ali@airesearch.us</email>
    </contact_backup>
    <investigator>
      <last_name>Sami Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern CT Hematology &amp; Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan C Johnson, PharmD, RPH, CACP</last_name>
      <phone>860-886-8362</phone>
      <email>drsusanjohnson@cox.net</email>
    </contact>
    <contact_backup>
      <last_name>Dennis Slater, MD</last_name>
      <phone>860-886-8362</phone>
      <email>drslater@echoct.org</email>
    </contact_backup>
    <investigator>
      <last_name>Dennis Slater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South Research Office</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rayanne Thompson</last_name>
      <phone>239-236-5681</phone>
      <email>rthompson@flcancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Fadi Kayali, MD</last_name>
      <email>fkayali@flcancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fadi Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaneska Chacin</last_name>
      <phone>561-447-0614</phone>
      <email>vchacin@brcrglobal.com</email>
    </contact>
    <contact_backup>
      <last_name>Harshad Amin, MD</last_name>
      <phone>561-447-0614</phone>
      <email>amin@brcrglobal.com</email>
    </contact_backup>
    <investigator>
      <last_name>Harshad Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North Research Office</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BJ Conklin</last_name>
      <phone>727-216-1143</phone>
      <email>bconklin@flcancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Vijay Patel, MD</last_name>
      <phone>727-216-1143</phone>
      <email>ViPatel@flcancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - East Research Office</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Asuncion, CCRP</last_name>
      <phone>561-366-4100</phone>
      <phone_ext>14753</phone_ext>
      <email>lasuncion@flcancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Todd Gersten, MD</last_name>
      <phone>(561) 366-4100</phone>
      <email>tgersten@flcancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Todd Gersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Alumbaugh, RN</last_name>
      <phone>225-761-3951</phone>
      <email>Aimee.Alumbaugh@aoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Michael Castine, MD</last_name>
      <phone>225-767-0822</phone>
      <email>michael.castine@aoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Castine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zangmeister Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Zangmeister, RN, OCN, CCRC</last_name>
      <phone>614-383-6236</phone>
      <email>Nancy.Zangmeister@aoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Jorge Rios-Perez, MD</last_name>
      <phone>(614) 383-6000</phone>
      <email>Jorge.Rios@aoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge Rios-Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Jordan</last_name>
      <phone>432-622-6212</phone>
      <email>mindy.jordan@sarahcannon.com</email>
    </contact>
    <contact_backup>
      <last_name>Davey Daniel, MD</last_name>
      <phone>432-622-6212</phone>
      <email>ddaniel@tnonc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Davey B. Daniel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mantegani</last_name>
      <phone>615-329-7289</phone>
      <email>Jennifer.Mantegani@SarahCannon.com</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Johnson, MD</last_name>
      <phone>615-524-4195</phone>
      <email>mjohnson@tnonc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced</keyword>
  <keyword>Metastatic</keyword>
  <keyword>NSCLC</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>NT-I7</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Non-Small Cell Lung Carcinoma</keyword>
  <keyword>Nonsmall Cell Lung Cancer</keyword>
  <keyword>efineptakin alfa</keyword>
  <keyword>efineptakin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

